Table 2 Quality characteristics of modelling studies
Author/Study (year of publication) | Brändle et al. [25] | Cameron et al. [21] | McEwan et al. [23] | Grima et al. [22] | Warren et al. [24] | Warren et al. [20] |
|---|---|---|---|---|---|---|
Research question clearly defined | (✓) | (✓) | ✓ | ✓ | ✓ | ✓ |
Perspective named | (✓) | (✓) | ✓ | ✓ | ✓ | ✓ |
Considered health effects | HbA1c, hypoglycaemia, fear of hypogl. | HbA1c, hypoglycaemia, fear of hypogl.1 | HbA1c, hypoglycaemia, fear of hypogl. | HbA1c | HbA1c1, hypoglycaemia, fear of hypogl. | HbA1c1, hypoglycaemia, fear of hypogl. |
Source of efficacy data | Meta-analysis2, Meta-regression | Meta-analysis | Meta-analysis2 | RCT | RCT | Meta-analysis, RCT |
Determination of efficacy via information synthesis | - | ✓ | ✓ | - | - | - |
Complications of diabetes considered | ✓ | ✓ | ✓ | ✓ | ✓1 | ✓1 |
All relevant costs considered | ✓ | (✓) | (✓) | (✓) | (✓) | (✓) |
Discounting (rate) | C (3,5%), E (3,5%) | C (5%), E (5%) | C (3,5%), E (3,5%) | C (5%), E (5%) | C (3,5%), E (3,5%) | C (3,5%), E (3,5%) |
Incremental analysis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Sensitivity analysis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Results of sensitivity analysis described | ✓ | ✓ | ✓ | ✓ | ✓ | (✓) |
Results presented per capita | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Research question answered | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Strength and weakness of studies discussed | - | ✓ | - | ✓ | (✓) | (✓) |